Topic Hub
60 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 60 of 60 clinical reviews.
A rigorous side-by-side comparison of four landmark statin trials across primary and secondary prevention populations, matched on absolute risk reduction, NNT, mortality benefit, and LDL-C lowering magnitude.
Read clinical reviewA physician-reviewed guide covering how ACE inhibitors and ARBs raise potassium, who is at highest risk, how to monitor, and what to do when levels rise, plus coverage of statin myopathy, anticoagulant bleeding risk, and beta-blocker bradycardia.
Read clinical reviewA physician-reviewed guide to amlodipine covering mechanism, dosing, side effects, drug interactions, and how it fits alongside atorvastatin, rosuvastatin, simvastatin, and ezetimibe in a cardiometabolic treatment plan.
Read clinical reviewA clinical breakdown of anticoagulant bleeding risk, including DOAC vs. warfarin data, risk scoring tools, and how to manage bleeding events on blood thinners.
Read clinical reviewEvidence-based comparison of apixaban (Eliquis), atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin (Zocor), and ezetimibe (Zetia) for cardiometabolic risk reduction. Includes dosing, trial data, interactions, and clinical decision guidance.
Read clinical reviewApoB outperforms LDL-C as a cardiovascular risk predictor in patients with metabolic syndrome, diabetes, or hypertriglyceridemia. The HealthRX Medical Team argues clinicians should order it routinely and stop waiting for payers to lead.
Read clinical reviewApoB counts every atherogenic particle in your blood. LDL-C only estimates cholesterol mass. Learn which marker predicts cardiovascular risk more accurately, when each test is ordered, and how statins, bempedoic acid, and PCSK9 inhibitors affect both numbers.
Read clinical reviewA physician-reviewed look at whether statin users need CoQ10 supplementation, what the evidence shows about statin-associated muscle symptoms, and when a clinician might actually recommend it.
Read clinical reviewShould you take daily aspirin to prevent a first heart attack or stroke? We break down the USPSTF 2022 guidelines, landmark trials, statin comparisons, and when low-dose aspirin is still appropriate.
Read clinical reviewA clinician-reviewed guide to atorvastatin (Lipitor) covering mechanism, doses from 10 mg to 80 mg, LDL reduction data, side-effect profile, and head-to-head comparisons with rosuvastatin (Crestor), simvastatin (Zocor), ezetimibe (Zetia), and bempedoic acid (Nexletol).
Read clinical reviewA clinician-reviewed guide to atrial fibrillation covering diagnosis, stroke risk, rate vs. rhythm control, anticoagulation, and its overlap with hypertension, metabolic syndrome, hyperlipidemia, and HFpEF.
Read clinical reviewA clinical deep-dive into bempedoic acid (Nexletol): mechanism, LDL-lowering data from CLEAR Outcomes, dosing, side effects, and head-to-head context with atorvastatin, rosuvastatin, simvastatin, and ezetimibe.
Read clinical reviewEvidence-based guide to antihypertensive medications that preserve exercise capacity, VO2max, and athletic performance while effectively lowering blood pressure.
Read clinical reviewBeta blockers lower heart rate by design, but bradycardia becomes a clinical problem when the rate drops too far. Learn the thresholds, drug interactions, and management steps backed by trial data.
Read clinical reviewA physician-reviewed guide to bisoprolol covering indications, dosing, side effects, drug interactions, and how it fits alongside statins like atorvastatin, rosuvastatin, and simvastatin in a cardiometabolic treatment plan.
Read clinical reviewA clinician-reviewed guide to blood pressure medication titration schedules, statin dose equivalence charts, and safe anticoagulant switching protocols. Includes specific doses, timelines, and guideline citations.
Read clinical reviewA clinician-reviewed guide covering the evidence on reversing atherosclerosis, optimal ApoB targets, statin use after 40, CoQ10 on statins, and the best BP medications for athletes.
Read clinical reviewA clinician-reviewed guide to cardiometabolic risk, performance, and metabolic health in athletes across sex, age, and pregnancy status. Covers GLP-1 therapy, diabetes management, and heart health with cited trials and guidelines.
Read clinical reviewA physician-reviewed guide to cardiometabolic disease in older adults, covering cardiovascular risk, type 2 diabetes, metabolic syndrome, GLP-1 therapies, hormone changes in women, gestational diabetes, and exercise physiology in aging athletes.
Read clinical reviewA comprehensive, clinician-reviewed guide to cardiometabolic disease in women, covering sex-specific risk factors, diabetes, pregnancy, older adults, and athletes, with current guidelines and named trial data.
Read clinical reviewA comprehensive clinical guide to cardiometabolic health covering risk factors, biomarkers, lifestyle interventions, GLP-1 medications, and evidence-based targets from major trials and guidelines.
Read clinical reviewA clinician-reviewed guide to carvedilol covering mechanism of action, approved indications, dosing protocols, side effects, drug interactions, and how it fits alongside lipid-lowering therapy with atorvastatin, rosuvastatin, simvastatin, and ezetimibe.
Read clinical reviewA clinician-reviewed guide to coronary artery disease covering atherosclerosis, risk factors, hypertension staging, hyperlipidemia, metabolic syndrome, HFpEF, diagnostic tests, and evidence-based treatment options.
Read clinical reviewInclisiran (Leqvio) costs roughly $3,250 per injection at list price. Learn about real-world pricing, Medicare Part B coverage, patient assistance, and how inclisiran compares to evolocumab, alirocumab, and generic statins.
Read clinical reviewA clinical breakdown of PCSK9 inhibitor costs, including evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). Covers list prices, net prices, insurance coverage, patient assistance programs, and how these drugs compare to generic statins.
Read clinical reviewA clinician-reviewed guide to managing diabetes in special populations, covering pregnancy, older adults, women, and athletes, with trial data, dose guidance, and guideline-backed recommendations.
Read clinical reviewStatins slightly raise new-onset diabetes risk in predisposed patients, but cardiovascular benefits outweigh this risk for most people. Evidence-based analysis of statin-diabetes link, CoQ10, apoB targets, and BP meds for athletes.
Read clinical reviewA clinical comparison of apixaban (Eliquis) and rivaroxaban (Xarelto) covering bleeding risk, dosing, renal dosing, reversal agents, drug interactions, and cost for AF, DVT, and PE indications.
Read clinical reviewA clinician-reviewed guide to ezetimibe (Zetia): mechanism of action, LDL reduction data, side-effect profile, and head-to-head comparisons with atorvastatin, rosuvastatin, simvastatin, and bempedoic acid.
Read clinical reviewA comprehensive clinical guide to familial hypercholesterolemia covering genetic basis, LDL thresholds, statin dosing, PCSK9 inhibitors, and connections to hypertension, metabolic syndrome, and heart failure with preserved EF.
Read clinical reviewA detailed breakdown of generic statin costs, PCSK9 inhibitor pricing, and inclisiran expenses. Compare atorvastatin, rosuvastatin, and simvastatin prices with and without insurance.
Read clinical reviewHeart failure with preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases. Learn how it differs from HFrEF, how metabolic syndrome drives it, and which treatments have the strongest evidence.
Read clinical reviewA clinician-reviewed guide to hydrochlorothiazide covering mechanism, dosing, side effects, drug interactions, and how it fits alongside statins like atorvastatin, rosuvastatin, and ezetimibe in a cardiometabolic treatment plan.
Read clinical reviewA clinician-reviewed comparison of Stage 1 and Stage 2 hypertension covering blood pressure thresholds, cardiovascular risk, metabolic syndrome overlap, heart failure subtypes, and evidence-based treatment protocols with real trial data.
Read clinical reviewLearn the difference between hypertensive urgency and emergency, how blood pressure stages connect to cardiometabolic risk, and exactly what to do when your reading tops 180/120 mmHg.
Read clinical reviewA clinician-reviewed guide to hypertriglyceridemia covering triglyceride classifications, cardiovascular risk, metabolic syndrome overlap, and evidence-based treatment options including fibrates, omega-3s, and GLP-1 agonists.
Read clinical reviewA clinician-reviewed guide to icosapent ethyl (Vascepa) covering FDA-approved indications, REDUCE-IT trial data, dosing, side effects, and how it compares to atorvastatin, rosuvastatin, simvastatin, and ezetimibe.
Read clinical reviewA complete clinical guide to inclisiran (Leqvio), a twice-yearly PCSK9 siRNA injection, compared with atorvastatin, rosuvastatin, simvastatin, and ezetimibe for LDL-C lowering and cardiovascular risk reduction.
Read clinical reviewVascepa (icosapent ethyl) costs $300-400/month without insurance. We analyze REDUCE-IT trial data, insurance coverage options, and whether the cardiovascular benefits justify the price for high-triglyceride patients.
Read clinical reviewA clinical comparison of lisinopril (ACE inhibitor) and losartan (ARB) covering mechanism, efficacy, side effects, organ-protection data, and how cardiometabolic context, ApoB, statins, anticoagulants, and beta-blockers, shapes the choice.
Read clinical reviewA physician-reviewed guide to lisinopril, atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin (Zocor), and ezetimibe (Zetia): how each drug works, what the trials show, dosing, side effects, and how they fit together in a cardiometabolic treatment plan.
Read clinical reviewA physician-reviewed guide to losartan covering mechanism, dosing, side effects, drug interactions, and how it fits alongside atorvastatin, rosuvastatin, simvastatin, and ezetimibe in a complete cardiometabolic treatment plan.
Read clinical reviewLearn what metabolic syndrome is, how it is diagnosed using ATP III and IDF criteria, how it relates to hypertension, hyperlipidemia, and heart failure, and which lifestyle and pharmacologic treatments have the strongest clinical evidence.
Read clinical reviewA physician-reviewed comparison of metoprolol and carvedilol covering mechanism, heart failure evidence, blood pressure control, side effects, drug interactions, and how to choose between them.
Read clinical reviewA clinician-reviewed guide to metoprolol (Lopressor, Toprol-XL), covering FDA-approved uses, dosing for hypertension and heart failure, side effects, and how it compares with statins like atorvastatin, rosuvastatin, and simvastatin in a complete cardiometabolic regimen.
Read clinical reviewA clinical deep-dive into niacin lipid use, covering mechanisms, dosing, trial outcomes, and how niacin fits alongside atorvastatin, rosuvastatin, simvastatin, and ezetimibe in modern dyslipidemia management.
Read clinical reviewA clinical overview of GLP-1 receptor agonist therapy across key patient populations including type 2 diabetes, older adults, women, and pregnancy considerations.
Read clinical reviewA clinical comparison of PCSK9 inhibitors (evolocumab, alirocumab) versus high-intensity statins (rosuvastatin, atorvastatin) for LDL reduction, cardiovascular outcomes, and patient selection.
Read clinical reviewA clinician-reviewed guide to cardiometabolic conditions in pregnancy, covering gestational diabetes management, GLP-1 receptor agonist safety, glucose targets, and long-term cardiovascular risk after delivery.
Read clinical reviewA clinician-reviewed guide to rivaroxaban (Xarelto): approved indications, dosing by indication, bleeding risks, drug interactions with statins like atorvastatin and rosuvastatin, and what the ROCKET AF and EINSTEIN trials actually showed.
Read clinical reviewA board-reviewed guide to rosuvastatin (Crestor) covering LDL reduction, head-to-head trial data versus atorvastatin and simvastatin, side effects, drug interactions, and when to add ezetimibe or bempedoic acid.
Read clinical reviewEvidence-based analysis of statin therapy for adults over 40, including USPSTF guidelines, ApoB targets, risk calculators, and when medication is truly warranted versus lifestyle alone.
Read clinical reviewA clinician-reviewed guide to simvastatin (Zocor) covering mechanism, doses, myopathy risk, drug interactions, and head-to-head comparisons with atorvastatin, rosuvastatin, ezetimibe, and bempedoic acid.
Read clinical reviewA clinician-reviewed guide to spironolactone for blood pressure control, including how it compares with atorvastatin, rosuvastatin, simvastatin, and ezetimibe in a full cardiometabolic treatment plan.
Read clinical reviewA clinician-reviewed statin dose equivalence chart with LDL-lowering intensity tiers, switching protocols, and guidance on titrating blood pressure meds and anticoagulants after a statin change.
Read clinical reviewA clinician-reviewed guide to statin myopathy covering muscle pain grading, CK thresholds, drug interactions, rechallenge protocols, and when to switch to alternative lipid-lowering therapy.
Read clinical reviewA clinical comparison of statins and bempedoic acid covering mechanism, LDL and ApoB reduction, side-effect profiles, drug interactions, and how to choose between them based on current ACC/AHA guidelines.
Read clinical reviewA physician-reviewed guide to switching anticoagulants safely, including warfarin-to-DOAC transitions, DOAC-to-DOAC switches, bridging protocols, INR timing, statin dose equivalence, and blood pressure medication titration during anticoagulation changes.
Read clinical reviewElevated lipoprotein(a) is a genetically determined cardiovascular risk factor. Learn what high Lp(a) levels mean, how they affect heart disease risk, and what treatment options exist.
Read clinical reviewLearn what a good apolipoprotein B (ApoB) level is, why it matters more than standard cholesterol panels, and how to lower it with lifestyle changes, statins, and other therapies.
Read clinical review